<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Cunningham, Muriel</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Grossman, Paul Michael</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">VLTS-394 Ineffective in the Treatment of Intermittent Claudication</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2006</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2006-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-14</style></pages><abstract><style  face="normal" font="default" size="100%">Patients with peripheral artery disease often experience difficulty walking and painful cramps because of the narrowing of arteries in the legs. This painful condition, known as intermittent claudication (IC), can range in severity from being mildly irritating to extremely debilitating. The efficacy and safety of VLTS-934, a compound believed to increase microvascular blood flow, was evaluated in a Phase 2b randomized, double-blind, placebo-controlled multicenter trial of patients with IC conducted in the United States.</style></abstract><number><style face="normal" font="default" size="100%">5</style></number><volume><style face="normal" font="default" size="100%">6</style></volume></record></records></xml>